Genta, S. and Araujo, D.V. and Hueniken, K. and Pipinikas, C. and Ventura, R. and Rojas, P. and Jones, G. and Butler, M.O. and Saibil, S.D. and Yu, C. and Easson, A. and Covelli, A. and Sauder, M.B. and Fournier, C. and Saeed Kamil, Z. and Rogalla, P. and Arteaga, D.P. and Vornicova, O. and Spiliopoulou, Pavlina and Muniz, T.P. and Siu, L.L. and Spreafico, A. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9 (11): 103978. ISSN 2059-7029

<img xmlns="http://www.w3.org/1999/xhtml" src="https://pub.demo35.eprints-hosting.org/117/1.haslightboxThumbnailVersion/345138.pdf" class="document_preview_tile_thumbnail"/> <span xmlns="http://www.w3.org/1999/xhtml" title="345138.pdf">345138.pdf</span>
345138.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (650kB)
Abstract

Background:
Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.
Patients and methods:
We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years.
Results:
ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-surgical sample). Positive ctDNA at landmark was associated with shorter overall survival (OS; median OS 22.7 months versus not reached, log-rank P value = 0.01) and a trend towards a shorter relapse-free survival (RFS; median RFS 15.7 months versus not reached, log-rank P value = 0.07). In 10 patients, ctDNA detection preceded disease relapse by a median of 128 days (range 8-406 days).
Conclusions:
Our data indicate that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence.

Information
Title Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients
Creators Genta, S. and Araujo, D.V. and Hueniken, K. and Pipinikas, C. and Ventura, R. and Rojas, P. and Jones, G. and Butler, M.O. and Saibil, S.D. and Yu, C. and Easson, A. and Covelli, A. and Sauder, M.B. and Fournier, C. and Saeed Kamil, Z. and Rogalla, P. and Arteaga, D.P. and Vornicova, O. and Spiliopoulou, Pavlina and Muniz, T.P. and Siu, L.L. and Spreafico, A.
Identification Number 10.1016/j.esmoop.2024.103978
Date November 2024
Divisions College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher Elsevier
Additional Information Funding This study was supported by the LIBERATE study (NCT03702309), which is an institutional liquid biopsy program at the University Health Network supported by the BMO Financial Group Chair in Precision Cancer Genomics (Chair held by Dr Lillian Siu). The following grants and awards have also contributed to supporting this study: Douglas Wright Melanoma Award—University of Toronto (SG), David Cornfield Melanoma Fund Award—University of Toronto (SG), ASCO Merit Award (SG), Cancer Genomic Program Grant—Princess Margaret Cancer Center (DVA) Division of Medical Oncology and Hematology Junior Faculty Award—Princess Margaret Cancer Center (AS), Catalyst and Invest in Research Princess Margaret grants—Princess Margaret Cancer Foundation (AS).
Library
URI https://pub.demo35.eprints-hosting.org/id/eprint/117
Item Type Article
Depositing User Unnamed user with email ejo1f20@soton.ac.uk
Date Deposited 11 Jun 2025 16:35
Revision 10
Last Modified 12 Jun 2025 11:55
View Item